^
Association details:
| Biomarker: | 6-gene WNT pathway signature |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | vantictumab (OMP-18R5) (Wnt signalling pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer
Excerpt:
A 6-gene WNT pathway signature showed significant association with progression-free survival (PFS) and overall survival (OS) for the biomarker high versus biomarker low groups (PFS: p = 0.029 and OS: p = 0.00045, respectively).
Secondary therapy:
paclitaxel
DOI:
10.1007/s10549-020-05817-w
Trial ID:
Source:
Title:
Abstract P3-07-57: Development of a 6-gene qPCR RUO-validated assay as a predictive biomarker for response of vantictumab (OMP-18R5; anti-frizzled) in HER2- breast cancer patients
Excerpt:
6-gene qPCR RUO-validated assay developed as a predictive biomarker for response of VAN in HER2-negative breast cancer patients;
DOI:
10.1158/1538-7445.SABCS15-P3-07-57
